

Change of leadership in the US

John Koconis, President & CEO of LEO US, has after careful consideration decided to resign from his post as head of our operation in the USA, effective June 1, 2014, and thus end his impressive career with LEO.

“We owe John significant gratitude for his tireless efforts in building our presence in the US from scratch – from three people, five card board boxes and an empty office into the large, professional and engaged patient-centric team that LEO US represents today,” said Lars Olsen, Executive Vice President, Global Sales & Marketing, LEO Pharma A/S in Denmark.

He underlines that John has secured that LEO Pharma’s endeavours in the US market have been profitable since day one – in contrast to many companies setting up in the US for the first time – effectively leading the company through two significant losses of exclusivity as well as heading the important but difficult and pain staking ground work in creating a platform for Picato® in the US.

John has been with LEO since 1998, working in various positions out of Greece, Denmark, Canada, the UK and latest the US.

“In all of his positions and in all of his time with LEO, John has proven himself a passionate leader and team-player, high on integrity and adaptability. His competencies, tenacity and knack for doing business will be greatly missed in LEO and I can only wish him the best of luck on the outside,” said Lars Olsen.

A search has been initiated to find John’s successor. To fill in during this search, Jørgen Damsbo Andersen, Regional Vice President at LEO Pharma A/S, will assume the role as Interim President and CEO of LEO US.